Lab data

Cagrilintide test results: how often vials pass lab testing

Cagrilintide is still in trials, and nearly half of recent research samples failed lab testing. Here are the numbers and how they compare with semaglutide, its partner in CagriSema.

12 November 2026 3 min read By Peptide AI Editorial policy

Of the last 198 Cagrilintide samples with a result in Finnrick's public lab-testing database, 107 passed and 91 failed: 54 percent of Cagrilintide test results were a pass. Another 2 came back incomplete and are left out. Finnrick has published 209 Cagrilintide tests from 47 sellers since 20 Apr 2025.

Cagrilintide is an investigational, long-acting amylin analog. Where semaglutide mimics GLP-1, cagrilintide mimics amylin, a hormone the pancreas releases with insulin. It is best known as half of CagriSema, an experimental combination with semaglutide. It is not approved on its own.

The short version

  • 54 percent of recent samples passed. 107 passed and 91 failed, of the last 198 with a result.
  • It is not FDA-approved as a standalone product, and there is no approved dosing schedule.
  • A pass is a narrow result. It covers identity, purity and fill for the vial that was tested. It does not cover endotoxin, sterility or the next batch.
  • We do not name sellers. The numbers describe the market, not any one shop.

Cagrilintide test results in numbers

MeasureCagrilintide
Published tests209
Sellers with at least one test47
First and latest test20 Apr 2025 to 2 Nov 2026
Recent results counted198 (2 incomplete left out)
Passed107
Failed91
Pass rate54%
Rank by pass rate9 of 14 on our peptide test results page

Figures from Finnrick's public Cagrilintide page, checked on 12 November 2026. They will change as new results come in.

What counts as a pass or a fail

These figures use Finnrick's "Purity focus" standard, the one its public pages show. A sample passes when its purity is at least 99.5 percent and the amount in the vial is within 35 percent of the label. A sample that turns out to be a different molecule fails under every standard Finnrick uses. Endotoxin testing is not required under this standard, so a pass says nothing about endotoxin or sterility.

The pass rate counts passes and fails among the most recent results on Finnrick's public page, up to 200, and leaves out tests that came back incomplete. Finnrick says it sources samples from sellers and sends them to third-party labs, with HPLC as the main method. Its methodology page has the detail.

Is cagrilintide FDA-approved?

No. Cagrilintide is not FDA-approved as a standalone product (see our cagrilintide page). It is not among the six peptides in HHS's October 2026 draft compounding policy, so there is no pharmacy route for it either.

Nearly half failed, and how it compares with semaglutide

Of the last 198 cagrilintide samples with a result, 91 failed and 107 passed. Semaglutide, its partner in CagriSema, passed 60 percent in the same database (semaglutide test results). Testing of cagrilintide started later: Finnrick has published 209 tests from 47 sellers since 20 Apr 2025.

Like retatrutide, cagrilintide has no approved product to hold a research vial against. The test result is the only evidence there is.

Before you buy Cagrilintide

There is no approved cagrilintide product, so a prescription is not an option today. Clinical trials are the only supervised route.

Before any order, three checks come first: the steps in how to vet a peptide supplier, an independent result for your own lot (how to get peptides tested), and the legal picture in is it legal to buy peptides. Products sold as research use only are not FDA-approved drugs, and a passing test does not make one safe to use.

Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.

Questions people ask

What percentage of Cagrilintide fails lab testing?

In Finnrick's public test database, 91 of the last 198 Cagrilintide samples with a result failed, which is 46 percent, and 107 passed. Tests that came back incomplete are left out.

Is Cagrilintide FDA-approved?

It is not FDA-approved as a standalone product, and there is no approved dosing schedule.

Does a passing lab test mean Cagrilintide is safe?

No. A pass means the sample matched its label on identity, purity and fill under one standard. It does not cover endotoxin, sterility, other vials, or whether Cagrilintide is safe or does anything in people.

Is cagrilintide the same as CagriSema?

No. CagriSema is an experimental combination of cagrilintide and semaglutide. Cagrilintide on its own is an amylin analog, and neither it nor the combination is an approved product.

Sources

  1. Methodology, Finnrick, accessed 12 November 2026
  2. Cagrilintide product page and public test history, Finnrick, accessed 12 November 2026
Free on iOS and Android

Log it once. See it all on one timeline.

Doses, food, training, labs, sleep and scans on one timeline. On iOS and Android.

The PeptideAI protocol screen with a weekly GLP-1 dose on it.